Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A – C-Raf

BACKGROUND: Recent advances in the treatment of melanoma that involve immunotherapy and B-Raf inhibition have revolutionised cancer care for this disease. However, an un-met clinical need remains in B-Raf inhibitor resistant patients where first-generation B-Raf inhibitors provide only short-term di...

Descripción completa

Detalles Bibliográficos
Autores principales: Blair, Connor M., Walsh, Nicola M., Littman, Bruce H., Marcoux, Frank W., Baillie, George S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434832/
https://www.ncbi.nlm.nih.gov/pubmed/30909892
http://dx.doi.org/10.1186/s12885-019-5489-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434832/
https://www.ncbi.nlm.nih.gov/pubmed/30909892
http://dx.doi.org/10.1186/s12885-019-5489-4

Ejemplares similares